Phitys I™ Percutaneous Left Ventricular Assist System Study

Shanghai NewMed Medical Co., Ltd.344 enrolled

Overview

The primary purpose of this clinical trial is to evaluate the safety and efficacy of the percutaneous left ventricular assist system versus intra-aortic balloon pump (IABP) for Circulatory Support during High-risk PCI.

This prospective, multi-center, randomized controlled clinical trial of the Percutaneous Ventricular Assist System is designed to measure the incidence of freedom from major adverse cardiovascular and cerebrovascular events (MACCE) at 30 days after PCI.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

344

Conditions

Coronary Artery Disease

Interventions

Percutaneous Ventricular Assist System（Phigine Medical）DEVICE

Percutaneous Ventricular Assist System or IABP provides intraoperative circulatory support during high-risk PCI.

intra-aortic balloon pump (IABP)DEVICE

IABP provides intraoperative circulatory support during high-risk PCI.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. 18 years old≤ patient age ≤90 years old AND patient is not in pregnancy or lactation; 2. Patients who have been evaluated by two or more cardiovascular surgeons as unsuitable for conventional surgery; or patients who have refused conventional surgery after adequate communication from the surgeon and who are at high risk for conventional surgery; 3. Left Ventricular Ejection Fraction (LVEF) ≤ 35% AND at least one of the following criteria: * Intervention on the last patent coronary conduit, or * Intervention on an unprotected left main coronary artery Or b) LVEF ≤ 30% and intervention in patient presenting with triple vessel disease. 4. Patient who can understand the purpose of the trial and volunteer to participate in, sign the informed consent form and are willing to accept relevant examinations and clinical follow-ups. Exclusion Criteria: 1. Pre-procedure cardiac arrest within 24 hours of enrolment requiring CPR; 2. Pre-procedure ST-segment myocardial infarction within 24 hours of enrolment; 3. Patient is in cardiogenic shock; 4. Mural thrombus in the left ventricle; 5. Post-infarction ventricular septal rupture, or atrial septal or ventricular septal defects; 6. The presence of mechanical aortic or mitral valve or heart constrictive device; 7. The presence of aortic stenosis (aortic orifice area ≤1.5cm²)； 8. The presence of moderate to severe aortic or mitral or tricuspid insufficiency; 9. The presence of severe peripheral vascular disease that would preclude the placement of the percutaneous mechanical circulatory assist device; 10. Severe aortic diseases such as aortic dissection and aortic aneurysm; 11. Active infective endocarditis or other active infections; 12. Chronic renal insufficiency (creatinine clearance≤30ml/min); 13. Liver dysfunction (elevation of liver enzymes and bilirubin levels to ≥3xULN or INR≥2); 14. The presence of uncorrectable abnormal coagulation (platelet count≤75,000/mm\^3 or INR≥2.0 or fibrinogen≤1.50 g/l); 15. The presence of uncorrected moderate to severe anemia (hemoglobin \<90 g/L); 16. History of stroke or TIA within 1 month of enrolment; 17. Allergy or intolerance to contrast media, anticoagulant and antiplatelet drugs (e.g., bivalirudin, low molecular heparin, aspirin, clopidogrel, Ticagrelor, etc.); 18. Participation in clinical trials of other drugs or medical devices prior to enrollment that have not yet reached the primary outcome of research; 19. Patient with poor compliance and could not complete the study as required determined by the investigator.

Locations (8)

The Second Hospital of Jilin University

Jilin City, Changchun, China

The First Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Henan Provincial Chest Hospital

Zhengzhou, Henan, China

Renmin Hospital of Wuhan University

Outcomes

Primary Outcomes

Incidence of freedom from major adverse cardiovascular and cerebrovascular events (MACCE)

MACCE defined as death, myocardial infarction, stroke, and target vessel revascularization.

Time frame: 30 days after procedure